RxDoctor Payments Data

Philip Lieu, MD

Ophthalmology · Desoto, TXNPI 1164740718

Payments from drug & device makers

$8,778in general payments, 2019–2025

Across 114 payments — averaging $77.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$3K
  • AbbVie$2K
  • Beaver-visitec International, Inc.$1K
  • ANI Pharmaceuticals, Inc.$326
  • Regeneron Healthcare Solutions, Inc.$276
  • Eyepoint US, Inc.$274
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$5,10358%
  • Food & beverage$3,67642%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,778 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$2,000,099
Medicare patients
654
Services billed
37,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac13$4,920
Prednisolone Acetate136$4,209
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha220$2,630
Bromfenac Sodium20$2,616
Difluprednate17$1,599
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat99$1,476
Acetazolamide ErAcetazolamide21$934
ErythromycinErythromycin Base55$678
Latanoprost38$299
Diclofenac Sodium28$285
Timolol Maleate50$264
Brimonidine Tartrate62$261
Methylprednisolone19$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$53$4,92013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →